88372-33-2

Usage

Uses

Used in Pharmaceutical Industry:
1-phenyl-2-(piperazin-1-yl)ethanone is used as a chemical precursor for the synthesis of a variety of drugs and active pharmaceutical ingredients. Its unique structure allows it to be a key component in the development of new medications.
Used in the Development of Anti-Anxiety Medications:
1-phenyl-2-(piperazin-1-yl)ethanone is used as a potential therapeutic agent for treating anxiety. Its role in this application is attributed to its capacity to interact with the nervous system and potentially alleviate symptoms associated with anxiety disorders.
Used in the Development of Antidepressant Medications:
Similarly, 1-phenyl-2-(piperazin-1-yl)ethanone is being studied for its potential use in the development of antidepressant medications, where it may help to regulate mood and counteract depressive symptoms.
Used in the Development of Antipsychotic Medications:
1-phenyl-2-(piperazin-1-yl)ethanone is used as a dopamine receptor antagonist, a property that makes it a candidate for the development of new antipsychotic medications aimed at treating conditions such as schizophrenia.
Used in Research for Treating Schizophrenia:
In the context of mental health research, 1-phenyl-2-(piperazin-1-yl)ethanone is being explored for its potential to treat schizophrenia, leveraging its antagonistic effect on dopamine receptors to manage the symptoms of the disorder.
While the therapeutic potential of 1-phenyl-2-(piperazin-1-yl)ethanone is promising, it is important to note that further research is necessary to fully understand its efficacy, optimal applications, and any possible side effects before it can be widely adopted in clinical settings.

InChI:InChI=1/C12H16N2O/c15-12(14-8-6-13-7-9-14)10-11-4-2-1-3-5-11/h1-5,13H,6-10H2

Upstream product

• 110-85-0 piperazine 
• 103-80-0 phenylacetyl chloride 
• 103-82-2 phenylacetic acid 
• 23776-85-4 N-(phenylacetyl)oxysuccinimide 
• 142-64-3 piperazine dihydrochloride 
• 55628-82-5 1-(Phenylacetyl)imidazole 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 
• 253175-91-6 tert-butyl 4-(2-phenylacetyl)piperazine-1-carboxylate 
• 7436-90-0 2,2-dibromostyrene 

Downstream Products

• 239100-92-6 1-phenylacetyl-4-[2-(tert-butoxycarbonylamino)acetyl]piperazine 
• 239100-94-8 1-phenylacetyl-4-[4-(tert-butoxycarbonylamino)butyryl]piperazine 
• 239100-93-7 1-phenylacetyl-4-[3-(tert-butoxycarbonylamino)propionyl]piperazine 
• 239100-95-9 1-phenylacetyl-4-[6-(tert-butoxycarbonylamino)hexanoyl]piperazine 
• 1054665-48-3 4-Phenylacetyl-piperazine-1-carboxylic acid (S)-((2R,3R,4S)-3-acetylamino-4-azido-6-methoxycarbonyl-3,4-dihydro-2H-pyran-2-yl)-((R)-2-oxo-[1,3]dioxolan-4-yl)-methyl ester 
• 1099094-41-3 9-(4-{4-[phenylacetyl]-piperazino}-butyl)-9H-fluorene-9-carboxylic acid-benzyl-amide 
• 461415-11-2 2-(4-chlorophenoxy)-1-(4-(2-phenylacetyl)piperazin-1-yl)ethanone 
• 1599431-86-3 2-(4-bromophenoxy)-1-(4-(2-phenylacetyl)piperazin-1-yl)ethanone 
• 1018574-27-0 2-chloro-1-(4-(2-phenylacetyl)piperazin-1-yl)ethanone 
• 1599431-88-5 (E)-1-(4-(2-phenylacetyl)piperazin-1-yl)-3-(p-tolyl)prop-2-en-1-one 
• 1599431-89-6 (E)-3-(4-methoxyphenyl)-1-(4-(2-phenylacetyl)piperazin-1-yl)prop-2-en-1-one 
• 1599431-90-9 (E)-3-(3,4-dichlorophenyl)-1-(4-(2-phenylacetyl)piperazin-1-yl)prop-2-en-1-one 
• 1599431-91-0 (E)-3-(3-fluoro-4-methylphenyl)-1-(4-(2-phenylacetyl)piperazin-1-yl)prop-2-en-1-one 
• 1599431-87-4 (E)-3-(4-bromophenyl)-1-(4-(2-phenylacetyl)piperazin-1-yl)prop-2-en-1-one 

Relevant academic research and scientific papers

Application of ethyl benzamide compound to preparation of local anesthetics

The invention provides an application of an ethyl benzamide compound to preparation of local anesthetics. The structure of the compound is shown in the following formula, and the compound has the characteristics of small toxic and side effects, short time

Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase

Human tissue transglutaminase (hTG2) is a multifunctional enzyme. It is primarily known for its calcium-dependent transamidation activity that leads to formation of an isopeptide bond between glutamine and lysine residues found on the surface of proteins, but it is also a GTP binding protein. Overexpression and unregulated hTG2 activity have been associated with numerous human diseases, including cancer stem cell survival and metastatic phenotype. Herein, we present a series of targeted covalent inhibitors (TCIs) based on our previously reported Cbz-Lys scaffold. From this structure-activity relationship (SAR) study, novel irreversible inhibitors were identified that block the transamidation activity of hTG2 and allosterically abolish its GTP binding ability with a high degree of selectivity and efficiency (kinact/KI > 105 M-1 min-1). One optimized inhibitor (VA4) was also shown to inhibit epidermal cancer stem cell invasion with an EC50 of 3.9 μM, representing a significant improvement over our previously reported "hit" NC9.

Oxazolo[4,5-b]pyridine-Based Piperazinamides as GSK-3β Inhibitors with Potential for Attenuating Inflammation and Suppression of Pro-Inflammatory Mediators

Recent studies reveal that glycogen synthase kinase-3β (GSK-3β) acts as a pro-inflammatory enzyme, and by inhibiting this kinase, inflammation can be controlled. In this regard, a series of 17 piperazine-linked oxazolo[4,5-b]pyridine-based derivatives was

Identification and characterization of small molecule modulators of the epstein-barr virus-induced gene 2 (EBI2) receptor

Oxysterols have recently been identified as natural ligands for a G protein-coupled receptor called EBI2 (aka GPR183) (Nature 2011, 475, 524; 519). EBI2 is highly expressed in immune cells (J. Biol. Chem. 2006, 281, 13199), and its activation has been sho

Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)- 2H-phthalazin-1-ones as potent PARP-1 inhibitors

We have developed a series of substituted 4-(thiophen-2-ylmethyl)-2H- phthalazin-1-ones as potent PARP-1 inhibitors. Preliminary biological evaluation indicated that most compounds possessed inhibitory potencies comparable to, or higher than AZD-2281. Among these compounds, 18q appeared to be the most notable one, which displayed an 8-fold improvement in enzymatic activity compared to AZD-2281. These efforts lay the foundation for our further investigation.

CDI-mediated monoacylation of symmetrical diamines and selective acylation of primary amines of unsymmetrical diamines

A highly efficient and green protocol for monoacylation of symmetrical diamines and chemoselective acylation of primary amines of unsymmetrical diamines has been developed.

Efficient and continuous monoacylation with superior selectivity of symmetrical diamines in microreactors

Efficient and continuous monoacylation of symmetrical diamines performed in microreactors yielded superior selectivity to that predicted by statistical considerations. It is highly valuable that the kinetically controlled product in high yields was achieved without any special catalyst at ambient temperature.

THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A1 , A2, A3, A4, A5, A6, A7, Asup